U. Paulus

1.1k total citations
24 papers, 588 citations indexed

About

U. Paulus is a scholar working on Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, U. Paulus has authored 24 papers receiving a total of 588 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pathology and Forensic Medicine, 11 papers in Pulmonary and Respiratory Medicine and 6 papers in Oncology. Recurrent topics in U. Paulus's work include Lymphoma Diagnosis and Treatment (14 papers), Lung Cancer Treatments and Mutations (11 papers) and Chronic Lymphocytic Leukemia Research (5 papers). U. Paulus is often cited by papers focused on Lymphoma Diagnosis and Treatment (14 papers), Lung Cancer Treatments and Mutations (11 papers) and Chronic Lymphocytic Leukemia Research (5 papers). U. Paulus collaborates with scholars based in Germany, United Kingdom and Democratic Republic of the Congo. U. Paulus's co-authors include Markus Loeffler, Volker Diehl, Jeremy Franklin, Christopher S. Potten, C.S. Potten, Hans Tesch, Juergen Wolf, M. Sieber, S. Chwalinski and Andreas Engert and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Cell Science and Annals of Oncology.

In The Last Decade

U. Paulus

23 papers receiving 562 citations

Peers

U. Paulus

ONCOL

PFM

PRM

GENET

Anna Guidetti Italy

Philippe C. Bishop United States

Diana O. Treaba United States

Thai M. Cao United States

F Rilke Italy

CN Abboud United States

Ricardo E. Duque United States

Sandra D. Bohling United States

Andrea Lamprecht Austria

C. De Micco France

Anna Guidetti Italy

U. Paulus

355 ×1.2

ONCOL

297 ×1.0

PFM

204 ×1.8

96 ×1.0

PRM

121 ×1.4

GENET

Citations per year, relative to U. Paulus U. Paulus (= 1×) peers Anna Guidetti

Countries citing papers authored by U. Paulus

Since Specialization

Citations

This map shows the geographic impact of U. Paulus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by U. Paulus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites U. Paulus more than expected).

Fields of papers citing papers by U. Paulus

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by U. Paulus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by U. Paulus. The network helps show where U. Paulus may publish in the future.

Co-authorship network of co-authors of U. Paulus

This figure shows the co-authorship network connecting the top 25 collaborators of U. Paulus. A scholar is included among the top collaborators of U. Paulus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with U. Paulus. U. Paulus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

David, A., et al.. (2023). Epidemiological profile of cancer at the laboratory of anatomy and pathological cytology of mungbere in the Democratic Republic of Congo. Journal of Cancer Policy. 37. 100434–100434.

Terschüren, Claudia, et al.. (2010). Are patients with Hodgkin lymphoma and high-grade non-Hodgkin lymphoma in clinical therapy optimization protocols representative of these groups of patients in Germany?. Annals of Oncology. 21(10). 2045–2051. 15 indexed citations

Reis, Andreas, et al.. (2006). Cost of illness of malignant lymphoma in Germany. European Journal of Cancer Care. 15(4). 379–385. 19 indexed citations

Paulus, U.. (2005). Therapieoptimierungsstudien und die Novelle des Arzneimittelgesetzes. Der Onkologe. 12(4). 325–330. 1 indexed citations

Sieber, M., Henning Bredenfeld, Andreas Josting, et al.. (2003). 14-Day Variant of the Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, and Prednisone Regimen in Advanced-Stage Hodgkin’s Lymphoma: Results of a Pilot Study of the German Hodgkin’s Lymphoma Study Group. Journal of Clinical Oncology. 21(9). 1734–1739. 52 indexed citations

Wiedenmann, S., Petra Schiller, U. Paulus, & Julia Wolf. (2002). Treatment of early and intermediate stage Hodgkin's lymphoma in the German Hodgkin's Lymphoma Study Group. Annals of Oncology. 13. 84–85. 7 indexed citations

Josting, Andreas, et al.. (2002). A randomized trial of chemotherapy with carmustine, etoposide, cytarabine, and melphalan (BEAM) plus peripheral stem cell transplantation (PBSCT) vs single-agent high-dose chemotherapy followed by BEAM plus PBSCT in patients with relapsed Hodgkin's disease (HD-R2). Annals of Hematology. 81(8). 424–429. 8 indexed citations

Ansén, Sascha, Andreas Engert, Juergen Wolf, et al.. (2001). Deutsche Hodgkin-Lymphom-Studiengruppe (DHSG): 20 Jahre Diagnostik, Therapie und Nachsorge von Patienten mit Morbus Hodgkin. Oncology Research and Treatment. 24(1). 35–48. 67 indexed citations

Franklin, Jeremy, U. Paulus, D. Lieberz, et al.. (2000). Is the international prognostic score for advanced stage Hodgkin’s disease applicable to early stage patients?. Annals of Oncology. 11(5). 617–624. 30 indexed citations

10.

Lieberz, D., M. Sextro, U. Paulus, et al.. (2000). How to restrict liver biopsy to high-risk patients in early-stage Hodgkin's disease. Annals of Hematology. 79(2). 73–78. 7 indexed citations

11.

Löffler, Markus, Dirk Hasenclever, Oana Brosteanu, U. Paulus, & Volker Diehl. (2000). Modell- und evidenzbasierte Planung klinischer Studien beim Hodgkin-Lymphom. Der Onkologe. 6(12). 1197–1201. 1 indexed citations

12.

Tesch, Hans, M. Sieber, Jens Ulrich Rüffer, et al.. (1999). 2 Cycles of ABVD Plus Radiotherapy Is More Effective Than Radiotherapy Alone in Early Stage HD—Interim Ahan Radiotherapy Alone in Early Stage HD—Interim Analysis of the HD7 Trial of the GHSG Clinic of Internal Medicine I University of Cologne/Germany. 1 indexed citations

13.

Diehl, Volker, Jeremy Franklin, M. Sieber, et al.. (1999). Increased Efficacy Through Moderate Dose Escalation of Chemotherapy: Interim Report From the HD9 Randomized Trial for Advanced Hodgkin’s Disease. 1 indexed citations

14.

Paulus, U., et al.. (1998). A dynamic model of proliferation and differentiation in the intestinal crypt based on a hypothetical intraepithelial growth factor. Cell Proliferation. 31(2). 93–110. 23 indexed citations

15.

Loeffler, Markus, et al.. (1997). Clonality and Life Cycles of Intestinal Crypts Explained by a State Dependent Stochastic Model of Epithelial Stem Cell Organization. Journal of Theoretical Biology. 186(1). 41–54. 65 indexed citations

16.

Wasielewski, Reinhard von, Michael Mengel, R. Fischer, et al.. (1997). Classical Hodgkin's disease. Clinical impact of the immunophenotype.. PubMed. 151(4). 1123–30. 102 indexed citations

17.

Paulus, U., et al.. (1992). A model of the control of cellular regeneration in the intestinal crypt after perturbation based solely on local stem cell regulation. Cell Proliferation. 25(6). 559–578. 74 indexed citations

18.

Potten, C.S., et al.. (1988). Scoring Mitotic Activity In Longitudinal Sections of Crypts of the Small Intestine. Cell Proliferation. 21(4). 231–246. 22 indexed citations

19.

Loeffler, Markus, Christopher S. Potten, U. Paulus, Jenna Glatzer, & S. Chwalinski. (1988). Intestinal Crypt Proliferation. Ii. Computer Modelling of Mitotic Index Data Provides Further Evidence For Lateral and Vertical Cell Migration In the Absence of Mitotic Activity. Cell Proliferation. 21(4). 247–258. 32 indexed citations

20.

Paulus, U. & János Hajdu. (1976). Dielectric response and kohn effect in strong magnetic fields. Solid State Communications. 20(7). 687–690. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact